SciCombinator

Discover the most talked about and latest scientific content & concepts.

LA Piras, F Riccardo, S Iussich, L Maniscalco, F Gattino, M Martano, E Morello, S Lorda Mayayo, V Rolih, F Garavaglia, R De Maria, E Lardone, F Collivignarelli, D Mignacca, D Giacobino, S Ferrone, F Cavallo and P Buracco
Abstract
Reported post-surgery 1-year survival rate for oral canine malignant melanoma (cMM) is around 30%; novel treatments are needed as the role of adjuvant chemotherapy is unclear. This prospective study regards adjuvant electrovaccination with human chondroitin sulfate proteoglycan-4 (hCSPG4)-encoded plasmid in 23 dogs with resected II/III-staged CSPG4-positive oral cMM compared with 19 dogs with resected only II/III-staged CSPG4-positive oral cMM. Vaccination resulted in 6-, 12-, 18- and 24-month survival rate of 95.6, 73.9, 47.8 and 30.4%, respectively [median survival time (MST) 684 days, range 78-1694, 8 of 23 dogs alive] and 6-, 12-, 18- and 24-month disease-free interval (DFI) rate of 82.6, 47.8, 26.1 and 17.4%, respectively (DFI 477 days, range 50-1694). Non-vaccinated dogs showed 6-, 12-, 18- and 24-month survival rate of 63.2, 26.3, 15.8 and 5.3%, respectively (MST 200 days, range 75-1507, 1 of 19 dogs alive) and 6-, 12-, 18- and 24-month DFI rate of 52.6, 26.3, 10.5 and 5.3%, respectively (DFI 180 days, range 38-1250). Overall survival and DFI of vaccinated dogs was longer in those <20 kg. In vaccinated and non-vaccinated dogs local recurrence rate was 34.8 and 42%, respectively while lung metastatic rate was 39 and 79%, respectively.
Tweets*
2
Facebook likes*
0
Reddit*
0
News coverage*
1
Blogs*
1
SC clicks
0
Concepts
Oncology, Vaccination, Cancer, Radiation therapy, Resection, Melanoma, Metastasis, Chemotherapy
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com